NYSE · SNY
Healthcare · Drug Manufacturers - General
$44.24
Down-$0.09 (-0.20%)
Updated Sep 8, 2026, 5:21 AM
SID Score
6.9/10
Composite research score
Smart Money
54/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SNY closed at $44.24 after 20 trading sessions, up 1.75% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 4, 2026 | $44.17 | $44.36 | $44.025 | $44.24 | 1.7M |
| Sep 3, 2026 | $45.15 | $45.16 | $44.20 | $44.33 | 2.4M |
| Sep 2, 2026 | $44.68 | $45.22 | $44.43 | $44.47 | 2.17M |
| Sep 1, 2026 | $45.08 | $45.23 | $44.205 | $44.37 | 2.02M |
| Aug 31, 2026 | $44.59 | $44.69 | $44.26 | $44.36 | 2.35M |
| Aug 28, 2026 | $44.93 | $44.96 | $44.65 | $44.82 | 1.36M |
| Aug 27, 2026 | $44.86 | $45.08 | $44.72 | $44.84 | 2.29M |
| Aug 26, 2026 | $46.01 | $46.04 | $45.39 | $45.42 | 1.63M |
| Aug 25, 2026 | $45.73 | $46.05 | $45.57 | $46.02 | 1.24M |
| Aug 24, 2026 | $45.49 | $45.78 | $45.32 | $45.69 | 1.72M |
| Aug 21, 2026 | $45.26 | $46.11 | $45.25 | $45.85 | 1.86M |
| Aug 20, 2026 | $45.65 | $45.74 | $45.06 | $45.15 | 2.6M |
| Aug 19, 2026 | $45.42 | $46.02 | $45.42 | $45.83 | 2.74M |
| Aug 18, 2026 | $45.10 | $45.22 | $44.735 | $44.97 | 3.17M |
| Aug 17, 2026 | $44.00 | $44.42 | $43.82 | $44.41 | 1.93M |
| Aug 14, 2026 | $43.51 | $43.80 | $43.235 | $43.72 | 2.72M |
| Aug 13, 2026 | $43.93 | $44.10 | $43.73 | $43.78 | 2.21M |
| Aug 12, 2026 | $43.49 | $43.78 | $43.34 | $43.71 | 2.93M |
| Aug 11, 2026 | $43.62 | $43.90 | $43.43 | $43.56 | 2.84M |
| Aug 10, 2026 | $43.53 | $43.705 | $43.32 | $43.48 | 3.36M |
The latest Smart Investors Daily articles mentioning SNY.
SNY research
Company profile and research snapshot.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 14, 2026 | TD COWEN | Hold | — |
| Jul 13, 2026 | ROTHSCHILD & CO REDBURN | Neutral | — |
| Jul 12, 2026 | DAY BY DAY | Sell | — |
| Jul 8, 2026 | BANCO SANTANDER | Outperform | — |
| Jul 1, 2026 | JEFFERIES | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 4, 2026
GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last...
Yahoo · Sep 2, 2026
Initiated the first-in-human Phase 1 trial of STX-1150, a novel LDL-C lowering therapy powered by ELXR, a highly engineered epigenetic silencing technology designed to deliver ultra-long-acting cholesterol lowering without permanent genetic changes Awarded more than $25 million from the California Institute for Regenerative Medicine (CIRM) to advance both STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering toward clinical entry Completed upsized initial public offering, including
Yahoo · Sep 1, 2026
LLY's $2.9B Merida deal adds immunology assets and expands its pipeline beyond obesity and diabetes into new growth areas.
SeekingAlpha · Aug 27, 2026
Corvus Pharmaceuticals has delivered strong soquelitinib data in atopic dermatitis, driving a significant market rally and a robust cash raise. Learn more about CRVS stock here.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SNY.
